Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kalpha and mTOR
Le, P.T., Cheng, H., Ninkovic, S., Plewe, M., Huang, X., Wang, H., Bagrodia, S., Sun, S., Knighton, D.R., LaFleur Rogers, C.M., Pannifer, A., Greasley, S., Dalvie, D., Zhang, E.(2012) Bioorg Med Chem Lett 22: 5098-5103
- PubMed: 22749419 
- DOI: https://doi.org/10.1016/j.bmcl.2012.05.100
- Primary Citation of Related Structures:  
4FA6, 4FAD - PubMed Abstract: 
Lead optimization efforts that employed structure base drug design and physicochemical property based optimization leading to the discovery of a novel series of 4-methylpyrido pyrimidinone (MPP) are discussed. Synthesis and profile of 1, a PI3Kα/mTOR dual inhibitor, is highlighted.
Organizational Affiliation: 
Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States. phuong.le@pfizer.com